[The role of regulatory T cells in the modulation of anti-tumor immune response]
- PMID: 23745355
- DOI: 10.2298/sarh1304262r
[The role of regulatory T cells in the modulation of anti-tumor immune response]
Abstract
Regulatory T cells (Treg) represent a subset of CD4+T cells whose function is to suppress immune responses. Treg lymphocytes can be divided into two subsets: natural nTreg lymphocytes that are developed in the thymus and inducible iTreg lymphocytes, which originate from conventional T lymphocytes on the periphery.The majority of Treg lymphocytes express high levels of interleukin-2 (IL-2) receptor a chain (CD25) and transcription factor FoxP3 (critical for the development and suppressor activity of iTreg lymphocytes). Cancer cells can modulate anti-tumor immune response indirectly, through the activation of Treg lymphocytes. It has been shown that the loss of regulatory function by depletion of tumor-induced Treg lymphocytes may enhance effectors response, resulting in tumor rejection, while the increased number of Treg lymphocytes effectively prevents tumor destruction. nTreg lymphocytes express increasingly CTLA-4 and membrane-bound TGF-beta, which inhibits cytokine production and responses of effectors lymphocytes.iTreg lymphocytes secrete immunosuppressive cytokines such as ILreg-10 and TGF-beta.Treg lymphocytes represent one of important obstruction in anti-tumor immunity.
Similar articles
-
TGF-β-Induced Regulatory T Cells Directly Suppress B Cell Responses through a Noncytotoxic Mechanism.J Immunol. 2016 May 1;196(9):3631-41. doi: 10.4049/jimmunol.1501740. Epub 2016 Mar 21. J Immunol. 2016. PMID: 27001954 Free PMC article.
-
Inducible and naturally occurring regulatory T cells enhance lung allergic responses through divergent transcriptional pathways.J Allergy Clin Immunol. 2017 Apr;139(4):1331-1342. doi: 10.1016/j.jaci.2016.06.051. Epub 2016 Aug 16. J Allergy Clin Immunol. 2017. PMID: 27542981 Free PMC article.
-
Cytokines affecting CD4(+) T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4(+)CD25(+) Treg.Transpl Immunol. 2013 Dec;29(1-4):51-9. doi: 10.1016/j.trim.2013.10.003. Epub 2013 Oct 16. Transpl Immunol. 2013. PMID: 24139939
-
Expanding and converting regulatory T cells: a horizon for immunotherapy.Arch Immunol Ther Exp (Warsz). 2009 May-Jun;57(3):199-204. doi: 10.1007/s00005-009-0021-1. Epub 2009 May 29. Arch Immunol Ther Exp (Warsz). 2009. PMID: 19479206 Review.
-
Regulatory T cells and tumor immunity.Cancer Immunol Immunother. 2005 Dec;54(12):1153-61. doi: 10.1007/s00262-005-0699-9. Epub 2005 May 3. Cancer Immunol Immunother. 2005. PMID: 15868167 Free PMC article. Review.
Cited by
-
A matrix metalloproteinase inhibitor enhances anti-cytotoxic T lymphocyte antigen-4 antibody immunotherapy in breast cancer by reprogramming the tumor microenvironment.Oncol Rep. 2016 Mar;35(3):1329-39. doi: 10.3892/or.2016.4547. Epub 2016 Jan 5. Oncol Rep. 2016. PMID: 26752000 Free PMC article.
-
Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1.J Exp Clin Cancer Res. 2018 Jan 4;37(1):1. doi: 10.1186/s13046-017-0664-4. J Exp Clin Cancer Res. 2018. PMID: 29301578 Free PMC article.
-
Tumor cell lysate induces the immunosuppression and apoptosis of mouse immunocytes.Mol Med Rep. 2014 Dec;10(6):2827-34. doi: 10.3892/mmr.2014.2606. Epub 2014 Oct 2. Mol Med Rep. 2014. PMID: 25310154 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
